stockrow
Saturday 7 November 2026
Export VSTM’s income statement to Excel — free account
Verastem, Inc.
VSTM Healthcare Biotechnology
Verastem, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $30.9 million, up 209.1% from fiscal 2024.
- Revenue
- +113.6%
- EPS
- +45.2%
- Free cash flow
- +24.5%
- Total debt
- +52.9%
Quarter to September 2026, against a year earlier
8.43
0.95
−10.13%
Follow VSTM
Alert me
| Sep '26 From the 10-Q filed 5 Nov | Jun '26 | Mar '26 | Dec '25 | Older periods | |
|---|---|---|---|---|---|
Piotroski F-Score |
— | 5 | — | — |
+8 more TTM periods Free account |
| 6,595.50% | (471.16%) | (786.15%) | (1,480.15%) | ||
| (88.02%) | (100.65%) | (107.90%) | (120.39%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(186.26%) | (206.78%) | (142.56%) | (138.59%) | |
Average Days of Receivables |
0.00 | 121.24 | 76.25 | 80.41 | |
Free Cash Flow per Share |
(1.58) | (1.62) | (1.54) | (1.98) | |
Free Cash Flow |
(159.57) | (162.19) | (150.95) | (137.51) | |
| Other line items | |||||
Cash ROIC |
(52.78%) | (62.36%) | (44.85%) | (40.62%) | |
Accounts Receivable Turnover |
0.00 | 5.58 | 9.39 | 8.88 | |
Accounts Payable Turnover |
0.00 | 0.92 | 0.99 | 0.64 | |
Inventory Turnover |
0.00 | 6.70 | 1.94 | 1.30 | |
Average Days of Payables |
0.00 | 550.04 | 419.78 | 856.78 | |
Days of Inventory on Hand |
0.00 | 73.22 | 99.98 | 126.16 | |
Tax Rate |
— | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
179.50% | 160.20% | 249.40% | 280.10% | |
Selling, General and Administrative Expense of Revenue |
100.34% | 108.73% | 178.33% | 198.33% | |
Share Based Compensation of Revenue |
11.18% | 11.06% | 19.49% | 22.98% | |
Interest Coverage |
(141.93) | (108.26) | (128.65) | (149.50) | |
Operating CF/Net income |
0.89 | 0.80 | 0.78 | 0.66 | |
Depreciation/Fixed assets |
— | 0.00 | 0.00 | 0.00 | |
Capex/Depreciation |
— | 0.00 | 0.00 | 0.00 | |
Revenue per Share |
0.99 | 0.87 | 0.50 | 0.59 | |
Operating CF per Share |
(1.58) | (1.62) | (1.54) | (1.98) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 |
Columns are period end dates · fundamentals updated 5 Nov 2026